Axe Compute Inc.
Close on Oct 19, 2026
- Market cap
- $159.26M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | After market close | $3.20M | $-0.87 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 18, 2026 | After market close | $35.00K | $-0.36 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | After market close | $3.62K | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | $2.68K | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 1, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 13, 2024 | Before market open | $345.69K | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 14, 2024 | Before market open | – | $-0.68 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | After market close | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | – | – |
Press releases
Announcements Axe Compute filed with the SEC
Axe Compute Takes Full Ownership of Georgia AI Cluster, Significantly Increasing the Contract’s Expected Free Cash Flow and Gross Margin
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Axe Compute and Duos Technologies Enter into Agreements For 55 MW of New AI Data Center Capacity Across Multiple U.S. Locations
Other events · EX-99.1 to Form 8-K
Axe Compute Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Axe Compute Secures $1.5 Billion Five-Year Dedicated AI Infrastructure Contract, Surpassing $3 Billion in 2026 Signed Contracted Value
Other events · EX-99.1 to Form 8-K
Axe Compute Secures Over $1.3 Billion in Global AI Infrastructure Customer Contracts
Other events · EX-99.1 to Form 8-K
The following risk factors supplement and update the risk factors disclosed in Part I, Item
Other events · EX-99.1 to Form 8-K
Axe Compute Inc. Reports First Quarter 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Axe Compute to Host Q1 2026 Financial Results Conference Call
Regulation FD disclosure · EX-99.1 to Form 8-K
Axe Compute Secures $260 million, Three-Year Enterprise Contract for 2,304-GPU NVIDIA B300 Deployment
Other events · EX-99.1 to Form 8-K
Axe Compute Reports $12 Million in Executed Agreements Providing $835 Thousand in Estimated Monthly Income Entering Q2 2026
Executive or director change · Other events · EX-99.1 to Form 8-K
Axe Compute Inc. Reports Full-Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Axe Compute Appoints Christopher Miglino as Chief Executive Officer, Ushering in a New Era of Decentralized Compute
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Predictive Oncology Becomes Axe Compute, Expanding Into High-Performance AI Infrastructure
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Oncology Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Predictive Oncology Reports Third Quarter 2025 Financial Results and Provides Update on Digital Asset Strategy
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Inc. Announces Closing of $343.5 Million in Private Placements to Initiate Digital Asset Treasury Strategy
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AETHIR DIGITAL ASSET TREASURY: POWERING THE AI INFRASTRUCTURE REVOLUTION Infrastructure - Backed Yield via the World’s Largest Decentralized GPU Network and $ATH Token CONFIDENTIAL DNA HOLDINGS VENTURES, INC
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Risks Related to the Company’s Business and Aethir Strategy and
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Predictive Oncology Inc. Announces Private Placements of $344 Million to Initiate a Digital Asset Treasury Strategy Focused on Aethir (ATH) Tokens
Regulation FD disclosure · EX-99.1 to Form 8-K
Predictive Oncology Announces 1-for-15 Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
0001446159 poai:SeriesAAndSeriesBWarrantsMember us-gaap:SubsequentEventMember 2025-03-25 2025-03-25
Other events · EX-99.1 to Form 8-K
Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Completes Sale of Skyline Medical Assets to DeRoyal Industries
Material agreement · Other events · EX-99.1 to Form 8-K
Predictive Oncology Announces Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Predictive Oncology Closes Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Announces Reverse Stock Split
Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Predictive Oncology Announces Distribution of Series F Preferred Stock to Holders of its Common Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K